Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use